FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ELK3-LIN7A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ELK3-LIN7A
FusionPDB ID: 26197
FusionGDB2.0 ID: 26197
HgeneTgene
Gene symbol

ELK3

LIN7A

Gene ID

2004

8825

Gene nameETS transcription factor ELK3lin-7 homolog A, crumbs cell polarity complex component
SynonymsERP|NET|SAP-2|SAP2LIN-7A|LIN7|MALS-1|MALS1|TIP-33|VELI1
Cytomap

12q23.1

12q21.31

Type of geneprotein-codingprotein-coding
DescriptionETS domain-containing protein Elk-3ELK3, ETS transcription factorELK3, ETS-domain protein (SRF accessory protein 2)ETS-related protein ERPETS-related protein NETSRF accessory protein 2serum response factor accessory protein 2protein lin-7 homolog Amammalian lin-seven protein 1tax interaction protein 33vertebrate LIN7 homolog 1
Modification date2020031320200313
UniProtAcc

P41970

Main function of 5'-partner protein: FUNCTION: May be a negative regulator of transcription, but can activate transcription when coexpressed with Ras, Src or Mos. Forms a ternary complex with the serum response factor and the ETS and SRF motifs of the Fos serum response element.

O14910

Main function of 5'-partner protein: FUNCTION: Plays a role in establishing and maintaining the asymmetric distribution of channels and receptors at the plasma membrane of polarized cells. Forms membrane-associated multiprotein complexes that may regulate delivery and recycling of proteins to the correct membrane domains. The tripartite complex composed of LIN7 (LIN7A, LIN7B or LIN7C), CASK and APBA1 associates with the motor protein KIF17 to transport vesicles containing N-methyl-D-aspartate (NMDA) receptor subunit NR2B along microtubules (By similarity). This complex may have the potential to couple synaptic vesicle exocytosis to cell adhesion in brain. Ensures the proper localization of GRIN2B (subunit 2B of the NMDA receptor) to neuronal postsynaptic density and may function in localizing synaptic vesicles at synapses where it is recruited by beta-catenin and cadherin. Required to localize Kir2 channels, GABA transporter (SLC6A12) and EGFR/ERBB1, ERBB2, ERBB3 and ERBB4 to the basolateral membrane of epithelial cells. {ECO:0000250|UniProtKB:Q8JZS0, ECO:0000269|PubMed:12967566}.
Ensembl transtripts involved in fusion geneENST idsENST00000228741, ENST00000552142, 
ENST00000549529, 
ENST00000552864, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score13 X 5 X 6=39012 X 5 X 4=240
# samples 137
** MAII scorelog2(13/390*10)=-1.58496250072116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/240*10)=-1.77760757866355
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ELK3 [Title/Abstract] AND LIN7A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ELK3 [Title/Abstract] AND LIN7A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ELK3(96617551)-LIN7A(81242101), # samples:1
Anticipated loss of major functional domain due to fusion event.ELK3-LIN7A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ELK3-LIN7A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ELK3-LIN7A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ELK3-LIN7A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneELK3

GO:0045892

negative regulation of transcription, DNA-templated

12933792

HgeneELK3

GO:0045944

positive regulation of transcription by RNA polymerase II

12788937



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:96617551/chr12:81242101)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ELK3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across LIN7A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000228741ELK3chr1296617551-ENST00000552864LIN7Achr1281242101-62415333201033237
ENST00000552142ELK3chr1296617551-ENST00000552864LIN7Achr1281242101-6078370157870237

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000228741ENST00000552864ELK3chr1296617551-LIN7Achr1281242101-0.0004061110.9995939
ENST00000552142ENST00000552864ELK3chr1296617551-LIN7Achr1281242101-0.0003978880.99960214

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ELK3-LIN7A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ELK3chr1296617551LIN7Achr128124210137071DKLSRALRYYYDKVYQYMHETITVNG
ELK3chr1296617551LIN7Achr128124210153371DKLSRALRYYYDKVYQYMHETITVNG

Top

Potential FusionNeoAntigen Information of ELK3-LIN7A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ELK3-LIN7A_96617551_81242101.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ELK3-LIN7Achr1296617551chr1281242101533HLA-A30:08KVYQYMHET0.93850.79171221
ELK3-LIN7Achr1296617551chr1281242101533HLA-A32:13YYYDKVYQY0.91750.6792817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B35:01YYYDKVYQY0.87080.6637817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:25YYYDKVYQY0.84380.7305817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:02YYYDKVYQY0.83860.7604817
ELK3-LIN7Achr1296617551chr1281242101533HLA-A02:21KVYQYMHET0.82830.65661221
ELK3-LIN7Achr1296617551chr1281242101533HLA-A02:20KVYQYMHET0.71220.5311221
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:01YYYDKVYQY0.37230.7826817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B58:02YYYDKVYQY0.25110.6272817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:04ALRYYYDKVY0.95830.6716515
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:02ALRYYYDKVY0.95520.5291515
ELK3-LIN7Achr1296617551chr1281242101533HLA-A32:13RYYYDKVYQY0.82660.7349717
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:05LRYYYDKVYQY0.99990.8294617
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:04LRYYYDKVYQY0.99990.6479617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:07YDKVYQYM0.99970.56721018
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:10YDKVYQYM0.99970.57081018
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:14YDKVYQYM0.99690.55551018
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:80YYDKVYQY0.99230.7969917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:67YYDKVYQY0.99230.7969917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:46YYDKVYQY0.99120.6589917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:10YYDKVYQY0.99060.8392917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:05YYDKVYQY0.99010.8386917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:27YYDKVYQY0.98650.8314917
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:21YYDKVYQY0.97180.7115917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:16YYDKVYQY0.9320.8454917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C05:09YYDKVYQYM0.99930.799918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C08:15YYDKVYQYM0.99830.885918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C01:17YYDKVYQYM0.99620.7267918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:05YYDKVYQYM0.98830.8999918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C03:07YYDKVYQYM0.98280.8963918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:10YYDKVYQYM0.98060.8738918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:03LRYYYDKVY0.97610.7846615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:29YYDKVYQYM0.9730.8195918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:67YYDKVYQYM0.97180.8323918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:80YYDKVYQYM0.97180.8323918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:27YYDKVYQYM0.97020.8798918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C03:14YYDKVYQYM0.95540.9302918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:06YYDKVYQYM0.94930.69918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:13YYDKVYQYM0.94810.7128918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C01:30YYDKVYQYM0.94570.7748918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:27LRYYYDKVY0.94020.8728615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:46YYDKVYQYM0.92930.6722918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:05LRYYYDKVY0.91880.8765615
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:05YYYDKVYQY0.87590.6084817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C08:13YYDKVYQYM0.86190.8676918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C08:04YYDKVYQYM0.86190.8676918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:31YYYDKVYQY0.84790.6283817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:21YYYDKVYQY0.82780.6841817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C08:03YYDKVYQYM0.81580.9198918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:67LRYYYDKVY0.78910.8363615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:80LRYYYDKVY0.78910.8363615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:10LRYYYDKVY0.77240.8722615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:46LRYYYDKVY0.74650.666615
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:21YYDKVYQYM0.74220.7231918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B39:12YYDKVYQYM0.73060.6418918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:80YYYDKVYQY0.70710.774817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:67YYYDKVYQY0.70710.774817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:16YYYDKVYQY0.66660.8429817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:10YYYDKVYQY0.65610.8296817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:29YYYDKVYQY0.64860.7839817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:46YYYDKVYQY0.60540.6191817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:27YYYDKVYQY0.56290.8221817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:16YYDKVYQYM0.54790.8833918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:13YYYDKVYQY0.41470.6757817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:12YYYDKVYQY0.39080.7694817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:05YYYDKVYQY0.34310.8212817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:04YYYDKVYQY0.27710.9645817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:03YYYDKVYQY0.27580.9636817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C15:04YYYDKVYQY0.25290.7058817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C03:14YYYDKVYQY0.17780.9009817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:16LRYYYDKVY0.02270.9356615
ELK3-LIN7Achr1296617551chr1281242101533HLA-B39:12YYYDKVYQY0.01190.543817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:10YYDKVYQYMH0.99510.6088919
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:07YYDKVYQYMH0.99440.6277919
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:16YYYDKVYQYM0.98920.8757818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:19RYYYDKVYQY0.97420.5713717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:05YYYDKVYQYM0.97250.8875818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:29YYYDKVYQYM0.9660.8094818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:80RYYYDKVYQY0.96160.852717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:67RYYYDKVYQY0.96160.852717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:27YYYDKVYQYM0.95880.8721818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:80YYYDKVYQYM0.95270.8175818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:67YYYDKVYQYM0.95270.8175818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:10RYYYDKVYQY0.95270.8809717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:10YYYDKVYQYM0.94970.8705818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:13YYYDKVYQYM0.94610.6675818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:46YYYDKVYQYM0.94610.6421818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:05RYYYDKVYQY0.94520.8648717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:46RYYYDKVYQY0.94460.76717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:27RYYYDKVYQY0.92720.8665717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:16RYYYDKVYQY0.79210.8543717
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:14LRYYYDKVYQY0.99980.6855617
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:03LRYYYDKVYQY0.9990.8568617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:27LRYYYDKVYQY0.99770.8614617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:67LRYYYDKVYQY0.99770.8321617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:80LRYYYDKVYQY0.99770.8321617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:10LRYYYDKVYQY0.99680.884617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:05LRYYYDKVYQY0.99620.8566617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:46LRYYYDKVYQY0.99590.7101617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:10YYYDKVYQYMH0.94250.9081819
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:67YYYDKVYQYMH0.9420.8754819
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:80YYYDKVYQYMH0.9420.8754819
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:46YYYDKVYQYMH0.89850.7629819
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:01YDKVYQYM0.99970.56721018
ELK3-LIN7Achr1296617551chr1281242101533HLA-C18:01YDKVYQYM0.99970.59911018
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:02YYDKVYQY0.99230.7969917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:17YYDKVYQY0.98770.8505917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:06YYDKVYQY0.97570.9211917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:04YYDKVYQY0.97060.5013917
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:04YYDKVYQY0.96360.8149917
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:07YYDKVYQY0.93960.708917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:03YYDKVYQY0.87950.7698917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:02YYDKVYQY0.87950.7698917
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:03RYYYDKVY0.58770.8121715
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:02RYYYDKVY0.58770.8121715
ELK3-LIN7Achr1296617551chr1281242101533HLA-C05:01YYDKVYQYM0.99930.799918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:03YYDKVYQYM0.99920.5259918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C18:01YYDKVYQYM0.99870.5029918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C01:03YYDKVYQYM0.99860.7947918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C08:02YYDKVYQYM0.99830.885918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:08LRYYYDKVY0.99810.505615
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:10LRYYYDKVY0.9980.6649615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C01:02YYDKVYQYM0.99680.72918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:09YYDKVYQYM0.98920.6261918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C03:67YYDKVYQYM0.97440.9444918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:17YYDKVYQYM0.97380.8897918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:02YYDKVYQYM0.97180.8323918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:04YYDKVYQYM0.96030.7885918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:04YYDKVYQYM0.93040.6443918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:03YYDKVYQYM0.91520.8434918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:02YYDKVYQYM0.91520.8434918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:17LRYYYDKVY0.88730.9138615
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:20YYYDKVYQY0.87770.7071817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B35:23YYYDKVYQY0.87480.644817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B35:77YYYDKVYQY0.87080.6637817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:12YYYDKVYQY0.86220.6428817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:39YYYDKVYQY0.84830.5833817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B35:11YYYDKVYQY0.84390.6974817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:06YYDKVYQYM0.84130.9535918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B35:20YYYDKVYQY0.8370.7552817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B35:28YYYDKVYQY0.83490.7254817
ELK3-LIN7Achr1296617551chr1281242101533HLA-A02:06KVYQYMHET0.82830.65661221
ELK3-LIN7Achr1296617551chr1281242101533HLA-A02:14KVYQYMHET0.82240.53941221
ELK3-LIN7Achr1296617551chr1281242101533HLA-C08:01YYDKVYQYM0.81580.9198918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:35YYYDKVYQY0.79770.7188817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B35:24YYYDKVYQY0.7930.762817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:02LRYYYDKVY0.78910.8363615
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:27YYYDKVYQY0.77470.7844817
ELK3-LIN7Achr1296617551chr1281242101533HLA-A32:01YYYDKVYQY0.76140.7746817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:22LRYYYDKVY0.75250.5838615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C16:01YYYDKVYQY0.73280.8929817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:08YYYDKVYQY0.7230.6778817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B35:43YYYDKVYQY0.72250.6766817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:11YYYDKVYQY0.72190.6823817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:02YYYDKVYQY0.70710.774817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:17YYYDKVYQY0.6490.8509817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:02YYDKVYQYM0.64770.8863918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:04YYYDKVYQY0.58420.7996817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:08YYDKVYQYM0.56670.9568918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C16:02YYYDKVYQY0.55720.9537817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:24YYYDKVYQY0.55010.7728817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:02YYDKVYQYM0.54880.9739918
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:17YYDKVYQYM0.54880.9739918
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:11YYYDKVYQY0.50150.7201817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:53YYYDKVYQY0.49120.7246817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C03:67YYYDKVYQY0.48960.9355817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:02YYYDKVYQY0.4760.8464817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C12:03YYYDKVYQY0.47330.8996817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C03:02YYYDKVYQY0.4470.8685817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:07YYYDKVYQY0.43570.7006817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:03YYYDKVYQY0.4040.759817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:54YYYDKVYQY0.39850.7017817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:08YYYDKVYQY0.3950.6489817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:08LRYYYDKVY0.39490.9486615
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:06YYYDKVYQY0.39230.75817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B18:05YYYDKVYQY0.37230.7826817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:17YYYDKVYQY0.32830.9623817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:02YYYDKVYQY0.32830.9623817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:04YYYDKVYQY0.29080.6568817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B48:02YYYDKVYQY0.27450.6825817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C15:09YYYDKVYQY0.25290.7058817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C16:04YYYDKVYQY0.20790.8747817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:10YYYDKVYQY0.17020.7008817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:04YYYDKVYQY0.12770.5583817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:03YYYDKVYQY0.07740.7603817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:02YYYDKVYQY0.07740.7603817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:06YYYDKVYQY0.04790.9147817
ELK3-LIN7Achr1296617551chr1281242101533HLA-B15:54LRYYYDKVY0.0350.6704615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:08YYYDKVYQY0.020.9497817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C02:10YYYDKVYQY0.0070.8935817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C02:02YYYDKVYQY0.0070.8935817
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:17LRYYYDKVY0.00270.9761615
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:02LRYYYDKVY0.00270.9761615
ELK3-LIN7Achr1296617551chr1281242101533HLA-A32:01KVYQYMHETI0.99770.94441222
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:01YYDKVYQYMH0.99440.6277919
ELK3-LIN7Achr1296617551chr1281242101533HLA-C18:01YYDKVYQYMH0.98860.6423919
ELK3-LIN7Achr1296617551chr1281242101533HLA-C03:67YYYDKVYQYM0.98610.9328818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:17YYYDKVYQYM0.9780.9719818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:02YYYDKVYQYM0.9780.9719818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:02RYYYDKVYQY0.96160.852717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:17YYYDKVYQYM0.95590.8797818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:02YYYDKVYQYM0.95270.8175818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C04:04YYYDKVYQYM0.94440.6074818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:17RYYYDKVYQY0.92990.8595717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:06YYYDKVYQYM0.92550.9486818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:08YYYDKVYQYM0.92540.9526818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:02YYYDKVYQYM0.91580.8325818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:03YYYDKVYQYM0.91580.8325818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:04YYYDKVYQYM0.90870.7634818
ELK3-LIN7Achr1296617551chr1281242101533HLA-C06:06RYYYDKVYQY0.76310.9404717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:02RYYYDKVYQY0.70760.8002717
ELK3-LIN7Achr1296617551chr1281242101533HLA-C14:03RYYYDKVYQY0.70760.8002717
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:10LRYYYDKVYQY0.99990.8044617
ELK3-LIN7Achr1296617551chr1281242101533HLA-B27:08LRYYYDKVYQY0.99990.6728617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:02LRYYYDKVYQY0.99770.8321617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:17LRYYYDKVYQY0.99660.8713617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:22LRYYYDKVYQY0.98680.526617
ELK3-LIN7Achr1296617551chr1281242101533HLA-C07:02YYYDKVYQYMH0.9420.8754819

Top

Potential FusionNeoAntigen Information of ELK3-LIN7A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ELK3-LIN7A_96617551_81242101.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ELK3-LIN7Achr1296617551chr1281242101533DRB1-0305ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB1-0305RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB1-0338ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB1-0338RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB1-0338SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB1-0338LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB1-0340ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB1-1222ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB1-1222RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB1-1510LSRALRYYYDKVYQY217
ELK3-LIN7Achr1296617551chr1281242101533DRB1-1510SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB1-1512LSRALRYYYDKVYQY217
ELK3-LIN7Achr1296617551chr1281242101533DRB1-1512SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0101ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0101RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0101SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0101LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0104ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0104RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0104SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0104LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0105ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0105RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0105SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0105LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0108ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0108RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0108SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0108LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0109ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0109RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0109SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0109LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0111ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0111RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0111SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0111LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0112ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0112RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0112SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0112LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0113ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0113RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0113SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0113LRYYYDKVYQYMHET621
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0114ALRYYYDKVYQYMHE520
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0114RALRYYYDKVYQYMH419
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0114SRALRYYYDKVYQYM318
ELK3-LIN7Achr1296617551chr1281242101533DRB3-0114LRYYYDKVYQYMHET621

Top

Fusion breakpoint peptide structures of ELK3-LIN7A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5580LRYYYDKVYQYMHEELK3LIN7Achr1296617551chr1281242101533

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ELK3-LIN7A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5580LRYYYDKVYQYMHE-7.9962-8.1096
HLA-B14:023BVN5580LRYYYDKVYQYMHE-5.70842-6.74372
HLA-B52:013W395580LRYYYDKVYQYMHE-6.83737-6.95077
HLA-B52:013W395580LRYYYDKVYQYMHE-4.4836-5.5189
HLA-A11:014UQ25580LRYYYDKVYQYMHE-10.0067-10.1201
HLA-A11:014UQ25580LRYYYDKVYQYMHE-9.03915-10.0745
HLA-A24:025HGA5580LRYYYDKVYQYMHE-6.56204-6.67544
HLA-A24:025HGA5580LRYYYDKVYQYMHE-5.42271-6.45801
HLA-B44:053DX85580LRYYYDKVYQYMHE-7.85648-8.89178
HLA-B44:053DX85580LRYYYDKVYQYMHE-5.3978-5.5112
HLA-A02:016TDR5580LRYYYDKVYQYMHE-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ELK3-LIN7A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ELK3-LIN7Achr1296617551chr12812421011018YDKVYQYMTATGACAAGGTGTATCAATATATG
ELK3-LIN7Achr1296617551chr12812421011221KVYQYMHETAAGGTGTATCAATATATGCATGAAACG
ELK3-LIN7Achr1296617551chr12812421011222KVYQYMHETIAAGGTGTATCAATATATGCATGAAACGATA
ELK3-LIN7Achr1296617551chr1281242101515ALRYYYDKVYGCCCTGCGATACTATTATGACAAGGTGTAT
ELK3-LIN7Achr1296617551chr1281242101615LRYYYDKVYCTGCGATACTATTATGACAAGGTGTAT
ELK3-LIN7Achr1296617551chr1281242101617LRYYYDKVYQYCTGCGATACTATTATGACAAGGTGTATCAATAT
ELK3-LIN7Achr1296617551chr1281242101715RYYYDKVYCGATACTATTATGACAAGGTGTAT
ELK3-LIN7Achr1296617551chr1281242101717RYYYDKVYQYCGATACTATTATGACAAGGTGTATCAATAT
ELK3-LIN7Achr1296617551chr1281242101817YYYDKVYQYTACTATTATGACAAGGTGTATCAATAT
ELK3-LIN7Achr1296617551chr1281242101818YYYDKVYQYMTACTATTATGACAAGGTGTATCAATATATG
ELK3-LIN7Achr1296617551chr1281242101819YYYDKVYQYMHTACTATTATGACAAGGTGTATCAATATATGCAT
ELK3-LIN7Achr1296617551chr1281242101917YYDKVYQYTATTATGACAAGGTGTATCAATAT
ELK3-LIN7Achr1296617551chr1281242101918YYDKVYQYMTATTATGACAAGGTGTATCAATATATG
ELK3-LIN7Achr1296617551chr1281242101919YYDKVYQYMHTATTATGACAAGGTGTATCAATATATGCAT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ELK3-LIN7Achr1296617551chr1281242101217LSRALRYYYDKVYQYCTGAGCAGAGCCCTGCGATACTATTATGACAAGGTGTATCAATAT
ELK3-LIN7Achr1296617551chr1281242101318SRALRYYYDKVYQYMAGCAGAGCCCTGCGATACTATTATGACAAGGTGTATCAATATATG
ELK3-LIN7Achr1296617551chr1281242101419RALRYYYDKVYQYMHAGAGCCCTGCGATACTATTATGACAAGGTGTATCAATATATGCAT
ELK3-LIN7Achr1296617551chr1281242101520ALRYYYDKVYQYMHEGCCCTGCGATACTATTATGACAAGGTGTATCAATATATGCATGAA
ELK3-LIN7Achr1296617551chr1281242101621LRYYYDKVYQYMHETCTGCGATACTATTATGACAAGGTGTATCAATATATGCATGAAACG

Top

Information of the samples that have these potential fusion neoantigens of ELK3-LIN7A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
SARCELK3-LIN7Achr1296617551ENST00000228741chr1281242101ENST00000552864TCGA-3B-A9HO-01A

Top

Potential target of CAR-T therapy development for ELK3-LIN7A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ELK3-LIN7A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ELK3-LIN7A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource